U.S. Market Expansion Continues as
Planned
SARASOTA, Fla., April 14,
2022 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ:
INVO) ("INVO" or the "Company"), a commercial-stage fertility
company focused on expanding access to advanced treatment worldwide
with its INVOcell® medical device and the intravaginal culture
("IVC") procedure it enables, today announced plans to open an INVO
Center in Kansas City, Missouri.
The Kansas City INVO Center will focus on patients in need of
advanced fertility care utilizing the efficient, effective, and
affordable INVOcell® solution. The Company currently has three
operational INVO Centers treating patients in Birmingham, Alabama, Atlanta, Georgia, and Monterrey, Mexico, with others scheduled to
open in the San Francisco and
Tampa areas.
"We are excited to announce Kansas
City as another ideal location for an INVO Center,"
commented Steve Shum, CEO of INVO.
"We are refining the process involved in opening an INVO Center and
are executing these initiatives simultaneously to improve
operational timelines and revenue ramp. This new INVO Center is
consistent with our stated expansion plans and represents a key
component of our strategy to expand access to advanced fertility
services for the significantly underserved patient population in
the U.S. and abroad."
The Company evaluates several criteria and data points as part
of its efforts to identify markets suitable for INVO Centers.
Based on an analysis of current population statistics, we believe
that Kansas City may have upwards
of 33,000 patients suffering with Infertility. With an
estimated 1,500 IVF treatments annually, there exists a large gap
of available care to treat local demand. Similar to other INVO
Centers, the Company expects to engage physician partners to
support its efforts in the Kansas
City market.
About INVO Bioscience
We are a commercial-stage fertility company dedicated to
expanding the assisted reproductive technology ("ART") marketplace
by making fertility care accessible and inclusive to people around
the world. Our flagship product is INVOcell®, a revolutionary
medical device that allows fertilization and early embryo
development to take place in vivo within the woman's body.
Our primary mission is to implement new medical technologies aimed
at increasing the availability of affordable, high-quality,
patient-centered fertility care. This treatment solution is the
world's first intravaginal culture technique for the incubation of
oocytes and sperm during fertilization and early embryo
development. This technique, designated as "IVC", provides patients
a more natural, intimate, and more affordable experience in
comparison to other ART treatments. The IVC procedure can deliver
comparable results at a fraction of the cost of traditional in
vitro fertilization ("IVF") and is a significantly more effective
treatment than intrauterine insemination ("IUI"). Our
commercialization strategy is focused on the opening of dedicated
"INVO Centers" offering the INVOcell® and IVC procedure (with three
centers in North America now
operational), in addition to continuing to sell our technology
solution into existing fertility clinics. For more information,
please visit www.invobio.com.
Safe Harbor Statement
This release includes forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended.
The Company invokes the protections of the Private Securities
Litigation Reform Act of 1995. All statements regarding our
expected future financial position, results of operations, cash
flows, financing plans, business strategies, products and services,
competitive positions, growth opportunities, plans and objectives
of management for future operations, as well as statements that
include words such as "anticipate," "if," "believe," "plan,"
"estimate," "expect," "intend," "may," "could," "should," "will,"
and other similar expressions are forward-looking statements. All
forward-looking statements involve risks, uncertainties and
contingencies, many of which are beyond our control, which may
cause actual results, performance, or achievements to differ
materially from anticipated results, performance, or achievements.
Factors that may cause actual results to differ materially from
those in the forward-looking statements include those set forth in
our filings at www.sec.gov. We are under no obligation to (and
expressly disclaim any such obligation to) update or alter our
forward-looking statements, whether as a result of new information,
future events or otherwise.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/invo-selects-kansas-city-as-additional-invo-center-location-301525484.html
SOURCE INVO Bioscience, Inc.